National Comprehensive Cancer Network

Patrick Creaven, MD, PhD

Roswell Park Cancer Institute

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Long H. Dang, MD, PhD

University of Michigan Comprehensive Cancer Center

Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment

Molecular Cancer Therapeutics

Manuel Hidalgo, MD, PhD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Assessment of Celecoxib Pharmacodynamics in Pancreatic Cancer

Molecular Cancer Therapeutics

Renuka Iyer, MD

Roswell Park Cancer Institute

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

British Journal of Cancer

Milind Javle, MD

Roswell Park Cancer Institute

Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Clinical Cancer Research

Robert Maki, MD, PhD

Memorial Sloan-Kettering Cancer Center

Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

Stacy Moulder, MD, MSCI

The University of Texas M.D. Anderson Cancer Center

Phase 2 Study of Gemcitabine and Irinotecan in Metastatic Breast Cancer with Correlatives to Determine Topoisomerase I Localization as a predictor of response

Brian Rini, MD

UCSF Helen Diller Family Comprehensive Cancer Center

Maximal COX-2 Immunostaining Predicts Clinical Response to Celecoxib and Interferon Alpha Therapy in Metastatic Renal Cell Carcinoma

Cancer

M. Wasif Saif, MD, MBBS

University of Alabama at Birmingham Comprehensive Cancer Center

A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Manisha Shah, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma

The Journal of Clinical Endocrinology & Metabolism

Manisha Shah, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

High-dose celecoxib does not improve survival of patients with differentiated thyroid cancer

Nature Clinical Practice Endocrinology & Metabolism

Charles L. Shapiro, MD

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Phase II Study of Sequentially Administered Low-dose Mitomycin-C (MMC) and Irinotecan (CPT-11) in Women with Metastatic Breast Cancer (MBC)

Annals of Oncology

Przemyslaw Twardowski, MD

City of Hope Comprehensive Cancer Center

Biologic Markers of Angiogenesis: Circulating Endothelial Cells in Patients with Advanced Malignancies Treated on Phase I Protocol with Metronomic Chemotherapy and Celecoxib

Cancer Investigation

Sam S. Yoon, MD

Massachusetts General Hospital

Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft Tissue Sarcoma

International Journal of Radiation Oncology* Biology*Physics